Management and treatment of chronic hepatitis B in HIV-positive patients

References

• Te H, Jensen D. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis. 2010;14:1–21.
   PubMedGoogle Scholar
• Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97–107.
   PubMed Web of Science ®Google Scholar
• Lok A, McMahon B. Chronic hepatitis B: update2009. Hepatology.2009;50:661–96.
   Google Scholar
• European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol. 2012;57:167–85.
   PubMed Web of Science ®Google Scholar
• Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to HAART and increased mortality in the EuroSIDA cohort. AIDS. 2005;19:2117–25.
   Google Scholar
• Soriano V, Puoti M, Peters M, Benhamou Y, Sulkowski M, Zoulim F, et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B virus international panel. AIDS. 2008;22:1399–410.
   PubMed Web of Science ®Google Scholar
• Thio C. Hepatitis B and Human immunodeficiency virus coinfection. Hepatology. 2009;49(Suppl):138–45.
   Google Scholar
• European AIDS Clinical Society Guidelines. Version 7.0. October 2013. Available at: http://www.europeanaidsclinicalsociety.org (accessed 6 March 2014).
   Google Scholar
• Kellerman S, Hanson D, McNaghten A, Fleming P. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in HIV-infected participants. J Infect Dis. 2003;188:571–7.
   PubMed Web of Science ®Google Scholar
• Modi A, Feld J. Viral hepatitis and HIV in Africa. AIDS Rev. 2007;9: 25–39.
   PubMed Web of Science ®Google Scholar
• Chun H, Fieberg A, Hullsied K, Lifson A, Crum-Cianflone NF, Weintrob A, et al. Epidemiology of hepatitis B virus infection in a US cohort of HIV-infected individuals during the past 20 years. Clin Infect Dis. 2010;50:426–36.
   PubMed Web of Science ®Google Scholar
• Wong V, Sung J. Diagnosis and personalized management of hepatitis B including significance of genotypes. Curr Opin Infect Dis. 2012; 25:570–7.
   PubMed Web of Science ®Google Scholar
• Soriano V, Mocroft A, Peters L, Rockstroh J, Antunes F, Kirkby N, et al. Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. J Antimicrob Chemother. 2010;65:548–55.
   PubMed Web of Science ®Google Scholar
• Soriano V, Sheldon J, Ramos B, Núñez M. Confronting chronic hepatitis B virus infection in HIV: new diagnostic tools and more weapons. AIDS. 2006;20:451–3.
   PubMed Web of Science ®Google Scholar
• Yeo W, Johnson P. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006;43: 209–20.
   PubMed Web of Science ®Google Scholar
• Milazzo L, Ebranati E, Cattaneo D, Gabanelli E, Lai A, Zehender G, et al. Recurrence of another hepatitis B virus escape mutant comes back in a patient infected with HIV and low CD4 + count. J Med Virol. 2014;86:97–101.
   PubMed Web of Science ®Google Scholar
• Pei R, Grund S, Verheyen J, Esser S, Chen X, Lu M. Spontaneous reactivation of hepatitis B virus replication in an HIV coinfected patient with isolated anti-Hepatitis B core antibodies. Virol J. 2014; 11:9.
   PubMed Web of Science ®Google Scholar
• McMahon B, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med. 2001;135:759–68.
   PubMed Web of Science ®Google Scholar
• Chan H, Leung N, Hussain M, Wong M, Lok A. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology. 2000;31: 763–8.
   PubMed Web of Science ®Google Scholar
• Grandjacques C, Pradat P, Stuyver L, Chevallier M, Chevallier P, Pichoud C, et al. Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. J Hepatol. 2000;33:430–9.
   PubMed Web of Science ®Google Scholar
• McMahon B. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49(Suppl):45–55.
   Google Scholar
• Iloeje U, Yang H, Su J, Jen C, You S, Chen C, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B virus viral load. Gastroenterology. 2006; 130:678–86.
   PubMed Web of Science ®Google Scholar
• Chen C, Yang H, Su J, Jen C, You S, Lu S, et al. Risk of hepatocellular carcinoma across biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73.
   PubMed Web of Science ®Google Scholar
• Puoti C, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis B in co-infected patients. J Hepatol. 2006;44:S65–70.
   PubMed Web of Science ®Google Scholar
• Walter S, Thein H, Amin J, Gidding HF, Ward K, Law M, et al. Trends in mortality after diagnosis of hepatitis B or C infection: 1992–2006. J Hepatol.2011;54:879–86.
   Google Scholar
• Martín-Carbonero L, Teixeira T, Poveda E, Plaza Z, Vispo E, Gonzalez-Lahoz J, et al. Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. AIDS. 2011;25:73–9.
   PubMed Web of Science ®Google Scholar
• Clifford G, Rickenbach M, Polesel J, Dal Maso L, Steffen I, Ledergerber B, et al. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS. 2008;22:2135–41.
   PubMed Web of Science ®Google Scholar
• Thio C, Seaberg E, Skolasky R, Phair J, Visscher B, Muñoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360:1921–6.
   Google Scholar
• Weber R, Sabin C, Friis-Moller N, Reiss P, El-Sadr W, Kirk O, et al. Liver related deaths in persons with the HIV: the D:A:D study. Arch Intern Med. 2006;166:1632–41.
   PubMed Web of Science ®Google Scholar
• Nikolopoulos G, Paraskevis D, Hatzitheodorou E, Moschidis Z, Sypsa V, Zavitsanos X, et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis. 2009;48:1763–71.
   PubMed Web of Science ®Google Scholar
• Hoffmann C, Seaberg E, Young S, Witt M, D’Acunto K, Phair J, et al. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients. AIDS. 2009;23:1881–9.
   PubMed Web of Science ®Google Scholar
• DHHS. Recommendations for use of antiretroviral drugs in HIV-1-infected adults and adolescents. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/.pdf.
   Google Scholar
• Thompson M, Aberg J, Hoy J, Telenti A, Benson C, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012;308: 387–402.
   PubMed Web of Science ®Google Scholar
• Soriano V, Tuma P, Vispo E, Labarga P, Fernández JV, Medrano J, et al. Hepatitis B in HIV patients: what is the current treatment and what are the challenges?J HIV Ther. 2009;14:13–18.
   PubMedGoogle Scholar
• Sulkowski M, Thomas D, Chaisson R, More R.Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection. JAMA. 2000;283:74–80.
   PubMed Web of Science ®Google Scholar
• Aceti A, Pasquazzi C, Zechini B, De Bac C; LIVERHAART Group. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr. 2002;29:41–8.
   PubMed Web of Science ®Google Scholar
• Soriano V, Puoti M, Garcia-Gascó P, Rockstroh J, Benhamou Y, Barreiro P, et al. Antiretroviral drugs and liver injury. AIDS. 2008; 22:1–13.
   PubMed Web of Science ®Google Scholar
• McMahon B, Jilek B, Brennan T, Shen L, Zhou Y, Wind-Rotolo M, et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med. 2007;356:2614–21.
   PubMed Web of Science ®Google Scholar
• Soriano V, Perelson A, Zoulim F. Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?J Antimicrob Chemother. 2008;62:1–4.
   PubMed Web of Science ®Google Scholar
• Known H, Lock M. Hepatitis B therapy. Gastroenterol Hepatol. 2011;8:275–84.
   Google Scholar
• Karatayli E, Karayalcin S, Karaaslan H, Kayhan H, Turkyilmaz A, Sahin F, et al. A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment. Antivir Ther. 2007;12:761–8.
   PubMed Web of Science ®Google Scholar
• Tenney D. Genotypic determinants and phenotypic properties of antiviral-resistant HBV variants: insight from entecavir resistance studies. Antivir Ther. 2010;15:529–35.
   PubMed Web of Science ®Google Scholar
• Sheldon J, Camino N, Rodes B, Bartholomeusz A, Kuiper M, Tacke F, et al. Selection of hepatitis B virus polymerase mutations in HIV coinfected patients treated with tenofovir. Antivir Ther. 2005;10: 727–34.
   PubMed Web of Science ®Google Scholar
• Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in HIV-infected patients. Hepatology. 1999;30:1302–6.
   PubMed Web of Science ®Google Scholar
• Hoffmann C, Charalambous S, Martin D, Innes C, Churchyard G, Chaisson R, et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis. 2008;47:1479–85.
   PubMed Web of Science ®Google Scholar
• Soriano V, Rivas P, Nuñez M. Risks and benefits of using antiretroviral therapy in HIV-infected patients with chronic hepatitis B in developing regions. Clin Infect Dis. 2008;47:1486–9.
   PubMed Web of Science ®Google Scholar
• Matthews G, Bartholomeusz A, Locarnini S. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS. 2006;20: 863–70.
   PubMed Web of Science ®Google Scholar
• Gouskos T, Wightman F, Chang J, Earnest-Silveira L, Sasadeusz J, Lewin S, et al. Severe hepatitis and prolonged hepatitis B virus-specific CD8 T-cell response after selection of hepatitis B virus YMDD variant in an HIV/hepatitis B virus co-infected patient. AIDS. 2004;18:1734–7.
   PubMed Web of Science ®Google Scholar
• Hsu C, Yeh C, Chang M, Liaw Y. Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance. Gastroenterology. 2007;132:543–50.
   PubMed Web of Science ®Google Scholar
• Sheldon J, Soriano V. Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Agents. 2008;61:766–8.
   Web of Science ®Google Scholar
• Martín-Carbonero L, Soriano V. New paradigms for treating hepatitis B in HIV/HBV co-infected patients. J Antimicrob Chemother. 2010; 65:379–82.
   PubMed Web of Science ®Google Scholar
• Thibault V, Aubron-Olivier C, Agut H, Katlama C. Primary infection with a lamivudine-resistant hepatitis B virus. AIDS. 2002;16:131–3.
   PubMed Web of Science ®Google Scholar
• Tuma P, Pineda J, Labarga P, Vidal F, Rodriguez C, Poveda E, et al. HBV primary drug resistance in newly diagnosed HIV-HBV-coinfected individuals in Spain. Antivir Ther. 2011;16:585–89.
   PubMed Web of Science ®Google Scholar
• Fujisaki S, Yokomaku Y, Shiino T, Koibuchi T, Hattori J, Ibe S, et al. Outbreak of infections by hepatitis B virus genotype A and transmission of genetic drug resistance in patients coinfected with HIV-1 in Japan. J Clin Microbiol. 2011; 49:1017–24.
   PubMed Web of Science ®Google Scholar
• Vutien P, Trinh H, García R, Nguyen HA, Levitt BS, Nguyen K, et al. Mutations in HBV DNA polymerase associated with nucleos(t)ide resistance are rare in treatment-naive patients. Clin Gastroenterol Hepatol. 2014; 12:1363–70.
   PubMed Web of Science ®Google Scholar
• Baxa D, Thekdi A, Golembieski A, Nguyen HA, Levitt BS, Nguyen K, et al. Evaluation of anti-HBV drug resistant mutations among patients with acute symptomatic hepatitis B in the United States. J Hepatol. 2013;58:212–16.
   PubMed Web of Science ®Google Scholar
• Xu Z, Liu Y, Xu T, Chen L, Si L, Wang Y, et al. Acute hepatitis B infection associated with drug resistant hepatitis B virus. J Clin Virol. 2010; 48:270–4.
   PubMed Web of Science ®Google Scholar
• Fung S, Mazulli T, El-Kashab M; and Canadian Association for the Study of the Liver. Lamivudine-resistant mutation among treatment-naïve hepatitis B patients is common and may be associated with treatment failure. American Association for the Study of Liver Diseases. 31 Oct–4 Nov 2008; San Francisco, CA, USA [Abstract 888].
   Google Scholar
• Soriano V, McMahon B. Rethinking therapeutic strategies for hepatitis B. Antivir Res. 2013;100:435–8.
   PubMedGoogle Scholar
• Lok A, Lai C, Leung N, Yao G, Cui Z, Schiff E, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125:1714–22.
   PubMed Web of Science ®Google Scholar
• Labarga P, Barreiro P, Martin-Carbonero L, Rodriguez-Novoa S, Medrano J, Rivas P, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS. 2009;23:689–96.
   PubMed Web of Science ®Google Scholar
• Del Palacio M, Romero S, Casado JL. Proximal tubular renal dysfunction or damage in HIV-infected patients. AIDS Rev. 2012;14:179–87.
   PubMed Web of Science ®Google Scholar
• Rifkin B, Perazella M. Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med. 2004;117:282–4.
   PubMed Web of Science ®Google Scholar
• Karras A, Lafaurie M, Furco A, Bourgarit A, Droz D, Sereni D, et al. Tenofovir-related nephrotoxicity in HIV-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis. 2003;36:1070–3.
   PubMed Web of Science ®Google Scholar
• Bedimo R, Maalouf N, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS. 2012;26:825–31.
   PubMed Web of Science ®Google Scholar
• Chen L, Zhang Q, Yu DM, Wan M, Zhang X.Early changes of HBV quasispecies during lamivudine treatment and the correlation with antiviral efficacy. J Hepatol. 2009;50:895–905.
   PubMed Web of Science ®Google Scholar
• Chang M, Chien R, Yeh C, Liaw Y. Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B. J Hepatol. 2005;43:72–7.
   PubMed Web of Science ®Google Scholar
• Koklu S, Tuna Y, Gulsen M, Demir M, Köksal AŞ, Koçkar MC, et al. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. Clin Gastroenterol Hepatol. 2013;11:88–94.
   PubMed Web of Science ®Google Scholar
• Kane M. Global programme for control of hepatitis B infection. Vaccine. 1995;13(Suppl):47–9.
   Google Scholar
• Schirmera P, Wintersb M, Holodniy M. HIV-HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance. J Clin Virol. 2011;52:261–4.
   PubMed Web of Science ®Google Scholar
• Gandhi R, Wurcel A, Lee H, McGovern B, Shopis J, Geary M, et al. Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J Infect Dis. 2005;191:1435–41.
   PubMed Web of Science ®Google Scholar
• Rivas P, Herrero MD, Puente S, Ramírez-Olivencia G, Soriano V. Immunizations in HIV-infected adults. AIDS Rev. 2007;9:173–87.
   PubMed Web of Science ®Google Scholar
• Launay O, van der Vliet D, Rosenberg AR, Michel ML, Piroth L, Rey D, et al. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA. 2011;305:1432–40.
   Google Scholar
• World Health Organization. Hepatitis B vaccines: WHO position paper. Wkly Epidemiol Rec. 2009;84:405–19.
   PubMedGoogle Scholar
• Wedemeyer H, Heidrich B, Manns M. Hepatitis D virus infection – not a vanishing disease in Europe! Hepatology. 2007;45:1331–2.
   Google Scholar
• Soriano V, Grint D, d’Arminio-Monforte A, Horban A, Leen C, Poveda E, et al. Hepatitis delta in HIV-infected individuals in Europe. AIDS. 2011;25:1987–92.
   PubMed Web of Science ®Google Scholar
• Calle-Serrano B, Manns MP, Wedemeyer H. Hepatitis delta and HIV infection. Semin Liver Dis. 2012;32:120–9.
   PubMed Web of Science ®Google Scholar
• Kew M. Hepatitis viruses (other than hepatitis B and C viruses) as causes of hepatocellular carcinoma: an update. J Viral Hepat. 2013; 20:149–57.
   PubMed Web of Science ®Google Scholar
• Farci P, Niro G. Clinical features of hepatitis D. Semin Liver Dis. 2012;32:228–36.
   PubMed Web of Science ®Google Scholar
• Erhardt A, Gerlich W, Starke C, Wend U, Donner A, Sagir A, et al. Treatment of chronic hepatitis D with pegylated interferon-a 2b. Liver Int. 2006;26:805–10.
   PubMed Web of Science ®Google Scholar
• Yurdaydin C. Treatment of chronic delta hepatitis. Semin Liver Dis. 2012;32:237–44.
   PubMed Web of Science ®Google Scholar
• Farci P, Roskams T, Chessa L, Peddis G, Mazzoleni A, Scioscia R, et al. Long-term benefit of interferon a therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology. 2004; 126:1740–9.
   PubMed Web of Science ®Google Scholar
• Niro G, Ciancio A, Gaeta G, Smedile A, Marrone A, Olivero A, et al. Pegylated interferon alpha 2b as monotherapy or in combination with ribavirin in chronic hepatitis D. Hepatology. 2006;44:713–20.
   PubMed Web of Science ®Google Scholar
• Yurdaydin C, Bozkaya H, Onder F, Sentürk H, Karaaslan H, Akdoğan M, et al. Treatment of chronic d hepatitis with lamivudine vs lamivudine + interferon vs interferon. J Viral Hepat. 2008;15: 314–21.
   PubMed Web of Science ®Google Scholar
• Wedemeyer H, Yurdaydìn C, Dalekos G, Erhardt A, Çakaloğlu Y, Değertekin H, et al.;HIDIT Study Group. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011;364: 322–31.
   PubMed Web of Science ®Google Scholar
• Sheldon J, Ramos B, Toro C, Ríos P, Martínez-Alarcón J, Bottecchia M, et al. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients?Antivir Ther. 2008;13:97–102.
   PubMed Web of Science ®Google Scholar
• Vispo E, Sierra-Enguita R, Barreiro P, Labarga P, Fernandez-Montero JV, de Mendoza C, et al. Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients. J Infect Dis. (In press).
   Google Scholar
• Wedemeyer H, Port K, Heidrich S; and HIDIT-2 Study Group. 96 weeks of pegylated interferon alpha-2a plus tenofovir or placebo for the treatment of hepatitis delta: the HIDIT-2 study. AASLD, Washington DC, November 2013 [abstract 31].
   Google Scholar
• Farci P. Treatment of chronic hepatitis D: new advances, old challenges. Hepatology. 2006;44:536–9.
   PubMed Web of Science ®Google Scholar
• Roche B, Samuel D. Liver transplantation in delta virus infection. Semin Liver Dis. 2012;32:245–55.
   PubMed Web of Science ®Google Scholar